Dr Reddy’s will license brands including Rebalanz, Celevida, Antoxid, Kidrich-D3, Becozinc in the nutrition, and OTC segments. The joint venture is expected to become operational in Q2 of FY’25.

Dr. Reddy's Laboratories Ltd. closed 18.86% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Nestlé India and Dr. Reddy’s Laboratories Ltd on Thursday announced that they have entered into a definitive agreement to form a joint venture to bring innovative nutraceutical brands to ...

HighTower Advisors LLC acquired a new position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) in the ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV Prasad of Dr Reddy's Laboratories. The company is focusing on diversifying ...

Dr. Reddy's Laboratories is among India’s leading ... segment after acquiring six OTC brands from US-based Ducere Pharma. Three years later in 2019, the company entered the nutrition business ...

Corient Private Wealth LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 447.3% in the ...

Dr. Reddy's Laboratories Ltd. closed 16.87% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dr. Reddy's Laboratories, USA, a wholly owned subsidiary of the company, has successfully completed the sale of all issued ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...